[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bladder-cancer-recurrence\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bladder-cancer-recurrence":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,53,82,114],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100637539","association-between-irrigation-fluid-absorption-and-perioperative-cfdna-dynamics-after-turbt-100637539",false,"NCT07589413","Association Between Irrigation Fluid Absorption and Perioperative cfDNA Dynamics After TURBT","A Predictive Model for Recurrence and Progression Risk After TURBT for Bladder Cancer on Intraoperative Irrigation Fluid Absorption Volume and Perioperative cfDNA Levels","Inclusion Criteria:\n\n1. Age 18 years or older.\n2. Suspected or histologically confirmed urothelial carcinoma of the bladder.\n3. Scheduled to undergo TURBT.\n4. Availability of sufficient peripheral blood samples for cfDNA extraction and mutation analysis.\n5. Availability of complete clinicopathological and perioperative data.\n6. Ability to provide informed consent and comply with study follow-up.\n\nExclusion Criteria:\n\n1. Non-urothelial bladder malignancy confirmed by pathology.\n2. History of other malignant tumors within the past 5 years, except adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix.\n3. Previous radical cystectomy or systemic antitumor therapy before enrollment.\n4. Inadequate blood sample quality or insufficient DNA yield for mutation analysis.\n5. Pregnancy or breastfeeding.\n6. Serious uncontrolled intercurrent illness that may interfere with study participation, follow-up, or compliance, including active infection, symptomatic congestive heart failure, unstable angina, clinically significant arrhythmia, severe psychiatric illness, or other conditions judged by the investigator to make participation unsuitable.","ALL","18 Years",{"count":19,"type":20},150,"ESTIMATED","OBSERVATIONAL","This prospective observational cohort study aims to evaluate the association between intraoperative irrigation fluid absorption and perioperative cell-free DNA (cfDNA) dynamics in patients undergoing transurethral resection of bladder tumor (TURBT). Eligible patients with suspected or confirmed bladder cancer scheduled for TURBT will be enrolled. Intraoperative irrigation fluid absorption volume will be recorded, and peripheral blood samples will be collected before surgery and within 24 hours after surgery for cfDNA extraction and mutation analysis.\n\nThe study will assess whether irrigation fluid absorption volume is associated with changes in cfDNA concentration, tumor-related mutation detection, and clinicopathological features, including tumor stage, grade, size, number, invasion depth, concomitant carcinoma in situ, operative time, resection depth, and intraoperative blood loss. Patients will also be followed for postoperative recurrence, progression, metastasis, and other adverse oncological outcomes.\n\nThis study may provide preliminary evidence for understanding perioperative tumor-related molecular changes during TURBT and may help improve risk stratification, perioperative management, and postoperative follow-up strategies for patients with bladder cancer.",[24,25,26,27,28],"Bladder (Urothelial, Transitional Cell) Cancer","Bladder Cancer Recurrence","Progression of Bladder Cancer","Transurethral Resection of Bladder Tumor","Urothelial Carcinoma of the Bladder",[30,31,32,33,34,35,36,37,38,39],"bladder cancer","nucleic acid mass spectrometry","TURBT","urothelial carcinoma","cell-free DNA","irrigation fluid absorption","circulating tumor DNA","mutation profiling","recurrence","progression","RECRUITING","2026-05-09",{"date":43,"type":44},"2026-05-15","ACTUAL",{"date":46,"type":44},"2026-04-01",{"date":48,"type":20},"2027-04-01",{"name":50,"class":51},"Zhiping Wang","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":52},"100625586","multiplex-mutation-detection-using-mass-spectrometry-in-bladder-cancer-100625586","NCT07424560","Multiplex Mutation Detection Using Mass Spectrometry in Bladder Cancer","Comprehensive Analysis of the Key Mutation Spectrum in Bladder Cancer: Establishment and Clinical Validation of a Multiplex Mutation Detection System Based on Nucleic Acid Mass Spectrometry","Inclusion Criteria:\n\n1. Histologically confirmed diagnosis of urothelial carcinoma of the bladder (any stage, including non-muscle invasive and muscle invasive).\n\n   \\-\n2. Availability of sufficient tumor tissue specimen (fresh frozen) for DNA extraction and mutation analysis.\n\n   \\-\n3. Age ≥ 18 years at time of diagnosis.\n\nExclusion Criteria:\n\n1. History of other malignant tumors within the past 5 years, except adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix.\n\n   \\-\n2. Inadequate quality or quantity of tumor tissue DNA for mutation panel analysis (e.g., severe DNA degradation, insufficient DNA yield).\n\n   \\-\n3. Pregnancy or breastfeeding.\n\n   \\-\n4. Serious uncontrolled intercurrent illness that would interfere with study follow-up or compliance, including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.",{"count":61,"type":20},400,"Bladder cancer is a highly heterogeneous malignancy characterized by frequent genetic alterations that are closely associated with disease progression, recurrence risk, and treatment response. However, existing mutation detection approaches are often limited by high cost, complex workflows, or insufficient capacity for multiplex and low-frequency mutation analysis, which restricts their routine clinical application. The purpose of this study is to establish and clinically validate a multiplex mutation detection system for bladder cancer based on nucleic acid mass spectrometry. Using fresh tumor tissue and matched adjacent normal tissue samples collected from patients with bladder cancer, a targeted mutation panel comprising key functional mutations with demonstrated clinical relevance will be constructed. The matched normal tissues serve as germline references to enable accurate identification of somatic mutations. The analytical performance of the system, including sensitivity, specificity, and concordance with whole-genome sequencing, will be systematically evaluated. In addition, the clinical utility of the mutation panel in risk stratification and treatment decision support will be explored by comparing its predictive value with established clinical models and guideline-recommended tools. The ultimate goal is to develop a cost-effective, reproducible, and clinically applicable molecular testing strategy that can support precision diagnosis and individualized management of patients with bladder cancer.",[64,25,65,26],"Bladder Cancer","Adjuvant Therapy for Bladder Cancer",[67,68,69,70,71,72],"Nucleic acid mass spectrometry","Bladder cancer","Gene mutations","High-throughput detection","Risk stratification","Adjuvant therapy sensitivity","2026-02-20",{"date":75,"type":44},"2026-02-24",{"date":77,"type":20},"2026-02-25",{"date":79,"type":20},"2028-07-01",{"name":81,"class":51},"Zhilong Dong",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":101,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":52},"100591612","anesthesia-modality-and-oncologic-outcomes-in-high-risk-nmibc-a-randomized-trial-100591612","NCT06982690","Anesthesia Modality and Oncologic Outcomes in High-Risk NMIBC: A Randomized Trial","Impact of Anesthesia Modality on Recurrence and Progression in High-Risk Non-Muscle Invasive Bladder Cancer: A Randomized Controlled Trial Comparing Spinal Versus General Anesthesia","Inclusion Criteria:\n\n* Age ≥40 years for male subjects or postmenopausal female subjects\n* ECOG performance status 0-2\n* Patients with suspected or newly diagnosed UBUC\n* ASA I or II\n* Patients with any other adequately treated Stage I or II cancer except UC, from which the subject has been disease free for 5 years\n* Adequate renal function, defined as a serum creatinine (Cre) concentration ≤ the institutional ULN\n* Adequate hepatic function, defined as total bilirubin ≤ the institutional ULN and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ the institutional upper limit of normal (ULN)\n\nExclusion Criteria:\n\n* Patients with prior or concurrent UC involving the renal pelvis, ureter or urethra\n* Patients with clinical evidence of MIBC or mUC\n* Immunocompromised or immunosuppressed patients\n* Patients with chronic use of anti-inflammatory agents or beta-blockers\n* Patients with difficult airways or other significant cardiovascular comorbidities (severe aortic stenosis, significant pulmonary disease, CHF) who are intolerant to GA\n* Patients with elevated intracranial pressure (ICP), primarily due to intracranial mass and trauma or infection at the site of SA\n* Patients with a serious uncontrolled medical disorder (e.g., trauma, fracture) or active infection that would impair their ability to receive spinal or GA\n* Patients with known allergies to propofol, fentanyl, sevoflurane, or bupivacaine\n* Subjects with a known history or family history of malignant hyperthermia\n* Subjects with bleeding diathesis","20 Years","80 Years",{"count":92,"type":20},370,"INTERVENTIONAL",[95],"NA","To demonstrate the superior efficacy of spinal anesthesia (SA) versus general anesthesia (GA) according to the delay of time to recurrence in high-risk NMIBC patients up to Week 104 after TURBT.",[98,32,24,25,99,100],"NMIBC","Anesthesia, General","Anesthesia,Spinal",[30,102,103,38,32],"general anesthesia","spinal anesthesia","NOT_YET_RECRUITING","2025-05-13",{"date":107,"type":44},"2025-05-21",{"date":109,"type":20},"2025-08-01",{"date":111,"type":20},"2029-11-30",{"name":113,"class":51},"National Taiwan University Hospital",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":93,"phases":123,"briefSummary":124,"conditions":125,"keywords":128,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":4},"100573852","xpert-bladder-monitor-a-non-invasive-follow-up-tool-for-detecting-relapse-in-high-grade-or-high-risk-bladder-cancer-100573852","NCT06751667","Xpert Bladder Monitor: a Non-Invasive Follow-Up Tool for Detecting Relapse in High Grade or High Risk Bladder Cancer","LIBERO","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Has a legally acceptable representative capable of understanding the informed consent document and providing consent on the participant's behalf\n* NMIBC high grade or high risk (already subjected to or currently undergoing treatment with BCG).\n* No contraindications to surgery\n\nExclusion Criteria:\n\n* Inability or unwillingness of the participant or their legal representative to provide written informed consent\n* Absolute contraindications to surgery or cystoscopy\n* Patients who have previously participated in clinical protocols involving chemotherapy drugs or immunotherapy\n* Patients with multiple recurrent tumors eligible for cystectomy or Muscle-Invasive Bladder Cancer (MIBC)",{"count":122,"type":20},50,[95],"Main objectives:\n\nQualitative and quantitative monitoring of recurrences in patients with a previous diagnosis of high-grade bladder cancer at high risk of persistence\u002Frecurrence.\n\nEndpoints: Presence or absence of mRNA in urine with a dichotomous result; concordance between Xpert BM and histopathological examination\n\nClinical relevance: reduces by half the number of (invasive) cystoscopies during follow-up. The non-invasive nature of the test could improve patient compliance with follow-up. Interventional study because it would reduce by half the number of cystoscopies during follow-up of bladder cancer which is considered the gold standard in the follow-up of this tumor. However, these markers are already CE validated and described in the European guidelines and for this reason the risk would be low.",[24,64,126,25,127],"Bladder Tumors","Cystoscopy",[129,130],"Xpert Bladder Monitor","Gene Xpert","2024-12-20",{"date":133,"type":44},"2024-12-30",{"date":135,"type":20},"2025-01-01",{"date":137,"type":20},"2032-01-01",{"name":139,"class":51},"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano"]